[Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study)].

Gusev EI, Skvortsova VI, Miasoedov NF, Nezavibat'ko VN, Zhuravleva EIu, Vanichkin AV

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova1 Jan 1997Cited by 6 (Europe PMC)

PMID11517472PepBankPUB-11517472

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanNon-randomized trialEfficacy outcome
In acute hemispheric ischemic stroke, adding Semax to combined intensive therapy increased the regress of general cerebral disorders compared with conventional therapy.
In plain wordsIn people with acute stroke, adding Semax to treatment sped up recovery from general brain symptoms compared with conventional therapy.
Peptide
Semax
Outcome
IncreaseRegress of general cerebral disorders
Study
n = 110
Comparator
Conventional therapy
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
Dose not stated · 5 and 10 days (treatment course)As given in this study (human).
Source sentences
Summary
It was established that including of Semax in combined intensive therapy of acute ischemic stroke had some influence on the rate of restoration of the damaged neurological functions in terms of increasing the regress of general cerebral and focal, especially motor disorders.
2 context sentences(design, population, supporting numbers)
Summary · context
Efficiency of Semax (synthetic derivative of ACTH-4-10) was studied in 30 patients in acute period of hemispherical ischemic stroke.
Summary · context
Control group consisted of 80 patients with the strokes analogous in severity and location of the damages and which were treated by conventional therapy.
Report a problemFND-1151747201
02HumanNon-randomized trialEfficacy outcome
In acute hemispheric ischemic stroke, adding Semax to combined intensive therapy increased the regress of focal, especially motor, disorders compared with conventional therapy.
In plain wordsIn people with acute stroke, adding Semax to treatment sped up recovery from focal and movement symptoms compared with conventional therapy.
Peptide
Semax
Outcome
IncreaseRegress of focal and motor disorders
Study
n = 110
Comparator
Conventional therapy
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
Dose not stated · 5 and 10 days (treatment course)As given in this study (human).
Source sentences
Summary
It was established that including of Semax in combined intensive therapy of acute ischemic stroke had some influence on the rate of restoration of the damaged neurological functions in terms of increasing the regress of general cerebral and focal, especially motor disorders.
2 context sentences(design, population, supporting numbers)
Summary · context
Efficiency of Semax (synthetic derivative of ACTH-4-10) was studied in 30 patients in acute period of hemispherical ischemic stroke.
Summary · context
Control group consisted of 80 patients with the strokes analogous in severity and location of the damages and which were treated by conventional therapy.
Report a problemFND-1151747202
03HumanNon-randomized trialEfficacy outcome
In patients with moderate ischemic stroke, the most effective daily dose of Semax was 12 mg.
In plain wordsIn people with moderate stroke, the authors found 12 mg of Semax per day worked best.
Peptide
Semax
Outcome
Not applicableMost effective daily dose in strokes of moderate severity
Study
n: not reported in source
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
12 mg daily · 5 and 10 days (treatment course)As given in this study (human).
Source sentences
Summary
The most effective daily doses were 12 mg for patients with strokes of moderate severity
2 context sentences(design, population, supporting numbers)
Summary · context
Efficiency of Semax (synthetic derivative of ACTH-4-10) was studied in 30 patients in acute period of hemispherical ischemic stroke.
Summary · context
Control group consisted of 80 patients with the strokes analogous in severity and location of the damages and which were treated by conventional therapy.
Report a problemFND-1151747203
04HumanNon-randomized trialEfficacy outcome
In patients with severe ischemic stroke, the most effective daily dose of Semax was 18 mg.
In plain wordsIn people with severe stroke, the authors found 18 mg of Semax per day worked best.
Peptide
Semax
Outcome
Not applicableMost effective daily dose in severe strokes
Study
n: not reported in source
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
18 mg daily · 5 and 10 days (treatment course)As given in this study (human).
Source sentences
Summary
The most effective daily doses were 12 mg for patients with strokes of moderate severity and 18 mg for patients with severe strokes (treatment course--5 and 10 days).
2 context sentences(design, population, supporting numbers)
Summary · context
Efficiency of Semax (synthetic derivative of ACTH-4-10) was studied in 30 patients in acute period of hemispherical ischemic stroke.
Summary · context
Control group consisted of 80 patients with the strokes analogous in severity and location of the damages and which were treated by conventional therapy.
Report a problemFND-1151747204

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 17:28 UTC
Study results updated
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.